Annual EBITDA
-$84.66 M
-$53.18 M-168.93%
December 31, 2023
Summary
- As of February 12, 2025, MLYS annual EBITDA is -$84.66 million, with the most recent change of -$53.18 million (-168.93%) on December 31, 2023.
- During the last 3 years, MLYS annual EBITDA has fallen by -$81.35 million (-2456.84%).
- MLYS annual EBITDA is now -2456.84% below its all-time high of -$3.31 million, reached on December 1, 2020.
Performance
MLYS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$60.09 M
-$14.94 M-33.07%
September 30, 2024
Summary
- As of February 12, 2025, MLYS quarterly EBITDA is -$60.09 million, with the most recent change of -$14.94 million (-33.07%) on September 30, 2024.
- Over the past year, MLYS quarterly EBITDA has dropped by -$32.38 million (-116.86%).
- MLYS quarterly EBITDA is now -827.54% below its all-time high of -$6.48 million, reached on June 1, 2022.
Performance
MLYS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$168.32 M
-$33.82 M-25.15%
September 30, 2024
Summary
- As of February 12, 2025, MLYS TTM EBITDA is -$168.32 million, with the most recent change of -$33.82 million (-25.15%) on September 30, 2024.
- Over the past year, MLYS TTM EBITDA has dropped by -$83.66 million (-98.82%).
- MLYS TTM EBITDA is now -2276.38% below its all-time high of -$7.08 million, reached on December 1, 2021.
Performance
MLYS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
MLYS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -168.9% | -116.9% | -98.8% |
| 3 y3 years | -2456.8% | -281.9% | -249.9% |
| 5 y5 years | -2456.8% | -281.9% | -249.9% |
MLYS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -336.8% | at low | -827.5% | at low | -2276.4% | at low |
| 5 y | 5-year | -2456.8% | at low | -827.5% | at low | -2276.4% | at low |
| alltime | all time | -2456.8% | at low | -827.5% | at low | -2276.4% | at low |
Mineralys Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$60.09 M(+33.1%) | -$168.32 M(+25.1%) |
| Jun 2024 | - | -$45.16 M(+27.7%) | -$134.50 M(+28.0%) |
| Mar 2024 | - | -$35.35 M(+27.6%) | -$105.07 M(+24.1%) |
| Dec 2023 | -$84.66 M(+168.9%) | -$27.71 M(+5.5%) | -$84.66 M(+26.4%) |
| Sep 2023 | - | -$26.27 M(+67.0%) | -$66.95 M(+39.2%) |
| Jun 2023 | - | -$15.73 M(+5.3%) | -$48.10 M(+23.8%) |
| Mar 2023 | - | -$14.94 M(+49.3%) | -$38.85 M(+23.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2022 | -$31.48 M(+62.4%) | -$10.01 M(+34.8%) | -$31.48 M(+10.2%) |
| Sep 2022 | - | -$7.42 M(+14.6%) | -$28.55 M(+35.1%) |
| Jun 2022 | - | -$6.48 M(-14.4%) | -$21.13 M(+44.2%) |
| Mar 2022 | - | -$7.57 M(+6.9%) | -$14.65 M(+106.9%) |
| Dec 2021 | -$19.38 M(+485.4%) | - | - |
| Dec 2021 | - | -$7.08 M | -$7.08 M |
| Dec 2020 | -$3.31 M | - | - |
FAQ
- What is Mineralys Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Mineralys Therapeutics?
- What is Mineralys Therapeutics annual EBITDA year-on-year change?
- What is Mineralys Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Mineralys Therapeutics?
- What is Mineralys Therapeutics quarterly EBITDA year-on-year change?
- What is Mineralys Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Mineralys Therapeutics?
- What is Mineralys Therapeutics TTM EBITDA year-on-year change?
What is Mineralys Therapeutics annual EBITDA?
The current annual EBITDA of MLYS is -$84.66 M
What is the all time high annual EBITDA for Mineralys Therapeutics?
Mineralys Therapeutics all-time high annual EBITDA is -$3.31 M
What is Mineralys Therapeutics annual EBITDA year-on-year change?
Over the past year, MLYS annual EBITDA has changed by -$53.18 M (-168.93%)
What is Mineralys Therapeutics quarterly EBITDA?
The current quarterly EBITDA of MLYS is -$60.09 M
What is the all time high quarterly EBITDA for Mineralys Therapeutics?
Mineralys Therapeutics all-time high quarterly EBITDA is -$6.48 M
What is Mineralys Therapeutics quarterly EBITDA year-on-year change?
Over the past year, MLYS quarterly EBITDA has changed by -$32.38 M (-116.86%)
What is Mineralys Therapeutics TTM EBITDA?
The current TTM EBITDA of MLYS is -$168.32 M
What is the all time high TTM EBITDA for Mineralys Therapeutics?
Mineralys Therapeutics all-time high TTM EBITDA is -$7.08 M
What is Mineralys Therapeutics TTM EBITDA year-on-year change?
Over the past year, MLYS TTM EBITDA has changed by -$83.66 M (-98.82%)